skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Informa pharma logo

Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Pharma Intelligence Logo
Search Icon Pharma Report StoreRecommendationsProduct loginProductLogin
Global Search Configuration

The Analysis

To investigate whether using Sitetrove data for site selection can enhance study enrollment performance, we conducted a retrospective analysis of a recently completed global Type 2 Diabetes trial, selected by the trial sponsor (a top-10 pharmaceutical company) for its enrollment success.

Sitetrove first pulled data on 14,341 investigators, representing the known global universe of investigators at the time of the analysis with confirmed clinical trial experience in this metabolic/endocrinology indication. Based on the requirements of the study protocol, Sitetrove then prioritized and ranked these investigators using a proprietary algorithm, including aspects of past experience and current trial involvement, to predict enrollment performance. Investigators were then grouped into three tiers based on their Sitetrove rating.

Following our independent analysis and ranking, data were compared against actual site-level performance data provided by the trial sponsor and average enrollment performance for actual investigators who fell in each tier was calculated.

ROI Analysis: Metabolic/Endocrinology, Global

Applying a data-driven approach to site selection using Sitetrove’s investigator intelligence service can increase average study site enrollment performance. For the actual clinical study analyzed herein, the number of sites needed to achieve target enrollment could have been reduced by 19%, with direct cost savings of over $900,000.
Diabetes
Download

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Request a free demo

Contact us for product technical and account support.

  • US Toll-Free   : +1 888 670 8900 
  • US Toll             : +1 212-600-3520
  • UK & Europe : +44 (0) 208 052 0700

Contact Customer Services

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now:

Shop now